Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • social determinants of health

    Healthcare setting

    Clinical research in 2026: The trends shaping tomorrow

    Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.

    Cuttsy + Cuttsy

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Kymera reports positive results in clinical trial for atopic dermatitis

    KT-621 could become a first-in-class, once-a-day oral treatment

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    Printed version of 'The participation equation'

    Behind the scenes: why we created ‘The participation equation’

    Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.

    Cuttsy + Cuttsy

    R:SQD logo

    Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success

    Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.

    Cuttsy + Cuttsy

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage

    Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...

    EatMoreFruit

    - PMLiVE

    GSK’s Blenrep approved by FDA for multiple myeloma

    Approval supported by positive results from phase 3 trial

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links